Santersus AG Receives Second US FDA Breakthrough Device Designation for NucleoCapture in Systemic Lupus Erythematosus
August 26, 2025Zurich, Switzerland, 26th Aug 2025 — Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NucleoCapture(tm) blood purification technology for the treatment of severe, treatment-refractory systemic lupus erythematosus (SLE). This marks the…